BioCentury
ARTICLE | Clinical News

Alpha galactosidase: Phase III started

June 13, 2016 7:00 AM UTC

Protalix began the double-blind, international Phase III BALANCE Study to compare 1 mg/kg IV PRX-102 vs. 1 mg/kg IV Fabrazyme agalsidase beta every 2 weeks for 2 years. The trial is enrolling 78 patients with impaired renal function who have been taking Fabrazyme for about 1 year and are on a stable dose for >=6 months before enrollment. ...